Responses

Download PDFPDF
Dopamine versus dobutamine in very low birthweight infants: endocrine effects
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Inotropes and cyanotic skin rash: worrisome side effects of dopamine.

    Editor, We read with great interest the article published by Filippi et al. (1) regarding the usefulness of dopamine in the treatment of hypotension in preterm, very low birth weight (VLBW) infants. Recently Dempsey and Barrington (2) reported how there are marked variations between neonatologists in interventions and treatments for neonatal hypotension. In medical literature is well reported how dopamine should be cons...

    Show More
    Conflict of Interest:
    None declared.